COTA Announces New Financing from Deerfield Management and Prior Investors To Accelerate Cancer Research and Treatment Innovation
New financing will help COTA expand RWD platform & services to drive more efficient and inclusive drug development.
Real-World Evidence is Now a “True End-to-End Capability” for Life Science Companies, Says Deloitte
Deloitte’s new Real-World Evidence Survey reveals that life sciences companies are now using real-world data (RWD) and real-world evidence (RWE) throughout the product life cycle—from early discovery through commercialization.
With Tailored, Fit-for-Purpose RWD from COTA, Life Science Companies Can Drive Innovation
Innovation is the key to success in the life sciences industry. But with the vast amounts of data being generated by clinical trials and other research, it can be difficult to know where to focus your efforts. COTA’s tailored, fit-for-purpose real-world data (RWD) can help.
Patient-Centered Drug Development Leads the Way in 2022
This will be the year that patient centricity drives drug development and care delivery decisions.
